Based on the Pliant Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Pliant Therapeutics Inc is USD 6.75 over the next 12 months. Pliant Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Pliant Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Pliant Therapeutics Inc’s stock price was USD 1.42. Pliant Therapeutics Inc’s stock price has changed by +13.60% over the past week, -7.79% over the past month and -89.96% over the last year.
No recent analyst target price found for Pliant Therapeutics Inc
No recent average analyst rating found for Pliant Therapeutics Inc
Company Overview Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Read Less
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and av...Read More
Frequently Asked Questions About Pliant Therapeutics Inc (PLRX) Stock
Based on ratings from 7 analysts Pliant Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on PLRX's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for PLRX is USD 6.75 over the next 12 months. The maximum analyst target price is USD 32 while the minimum anlayst target price is USD 1.5.
Unfortunately we do not have enough data on PLRX's stock to indicate if its overvalued.
The last closing price of PLRX's stock was USD 1.42.
The most recent market capitalization for PLRX is USD 0.08B.
Based on targets from 7 analysts, the average taret price for PLRX is projected at USD 6.75 over the next 12 months.
This means that PLRX's stock price may go up by +375.35% over the next 12 months.
We can't find any ETFs which contains Pliant Therapeutics Inc's stock.
As per our most recent records Pliant Therapeutics Inc has 171 Employees.
Pliant Therapeutics Inc's registered address is 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Pliant Therapeutics Inc's website at https://pliantrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Pliant Therapeutics Inc (PLRX) Stock
Based on ratings from 7 analysts Pliant Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 8 hold ratings.
Unfortunately we do not have enough data on PLRX's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for PLRX is USD 6.75 over the next 12 months. The maximum analyst target price is USD 32 while the minimum anlayst target price is USD 1.5.
Unfortunately we do not have enough data on PLRX's stock to indicate if its overvalued.
The last closing price of PLRX's stock was USD 1.42.
The most recent market capitalization for PLRX is USD 0.08B.
Based on targets from 7 analysts, the average taret price for PLRX is projected at USD 6.75 over the next 12 months.
This means that PLRX's stock price may go up by +375.35% over the next 12 months.
We can't find any ETFs which contains Pliant Therapeutics Inc's stock.
As per our most recent records Pliant Therapeutics Inc has 171 Employees.
Pliant Therapeutics Inc's registered address is 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Pliant Therapeutics Inc's website at https://pliantrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PLRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
